Abstract
Objective: Current standard therapy for advanced or recurrent cervical cancer is combination chemotherapy with paclitaxel or topotecan based on cisplatin chemotherapy. However, this combination chemotherapy shows only a 27%~36% response rate. Therefore, there have been many efforts to discover other combination therapeutic agents for cervical cancer. Tetraarsenic oxide (TAO) showed the possibility of therapeutic effect in previous in vitro and in vivo studies with cervical cancer cell lines. The purpose of this study was to investigate the anticancer effect of TAO in an in vivo study using a patient-derived xenograft (PDX) mouse model and to reveal the mechanisms of TAO acting on tumor cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
